(Q37803577)

23 August 2017

title

Pharmacotherapy of disruptive behavior in mentally retarded subjects: A review of the current literature (English)

1 reference

23 August 2017

0 references

Frank Hässler

1

1 reference

23 August 2017

Olaf Reis

series ordinal

2

1 reference

23 August 2017

publication date

1 January 2010

1 reference

Developmental Disabilities Research Reviews

23 August 2017

published in

1 reference

23 August 2017

volume

16

1 reference

23 August 2017

issue

3

1 reference

23 August 2017

page(s)

265-272

1 reference

Failure of naltrexone hydrochloride to reduce self-injurious and autistic behavior in mentally retarded adults. Double-blind placebo-controlled studies.

23 August 2017

cites work

1 reference

Double-blind, placebo-controlled trial of clonidine in hyperactive children with mental retardation

21 January 2018

1 reference

7 January 2021

Methylphenidate treatment in children with borderline IQ and mental retardation: analysis of three aggregated studies

1 reference

7 January 2021

Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence

1 reference

7 January 2021

The Nisonger CBRF: a child behavior rating form for children with developmental disabilities

1 reference

7 January 2021

Psychopharmacological treatments in persons with dual diagnosis of psychiatric disorders and developmental disabilities

1 reference

7 January 2021

The psychiatric symptoms, diagnoses and care needs of 100 mentally handicapped patients.

1 reference

7 January 2021

Efficacy and specificity of pharmacological therapies for behavioral disorders in persons with mental retardation.

1 reference

7 January 2021

Psychotropic drug prescribing in child and adolescent learning disability psychiatry.

1 reference

7 January 2021

Selective serotonin re-uptake inhibitors for the treatment of perseverative and maladaptive behaviours of people with intellectual disability.

1 reference

7 January 2021

Open-label treatment with risperidone of 26 psychiatrically-hospitalized children and adolescents with mixed diagnoses and aggressive behavior.

1 reference

7 January 2021

Psychopharmacology and aggression. I: A meta-analysis of stimulant effects on overt/covert aggression-related behaviors in ADHD.

1 reference

7 January 2021

Risperidone in children with disruptive behavior disorders and subaverage intelligence: a 1-year, open-label study of 504 patients

1 reference

7 January 2021

Pervasive developmental disorder, behavior problems, and psychotropic drug use in children and adolescents with mental retardation.

1 reference

7 January 2021

Mental disorder in adults with intellectual disability. 2: The rate of behaviour disorders among a community-based population aged between 16 and 64 years.

1 reference

7 January 2021

Psychotropic medication for behaviour problems in people with intellectual disability: a review of the current literature

1 reference

7 January 2021

Practical guidelines for the use of new generation antipsychotic drugs (except clozapine) in adult individuals with intellectual disabilities.

1 reference

7 January 2021

Efficacy and safety of naltrexone use in pediatric patients with autistic disorder

1 reference

7 January 2021

Prevalence of psychiatric disorders in children and adolescents with and without intellectual disability

1 reference

7 January 2021

Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ.

1 reference

7 January 2021

A double-blind pilot study of risperidone in the treatment of conduct disorder

1 reference

7 January 2021

Quetiapine in nine youths with autistic disorder

1 reference

7 January 2021

Effectiveness, safety, and pharmacokinetics of quetiapine in aggressive children with conduct disorder

1 reference

7 January 2021

Short- and long-term efficacy and safety of risperidone in adults with disruptive behavior disorders

1 reference

7 January 2021

ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes

1 reference

7 January 2021

Zuclopenthixol in adults with intellectual disabilities and aggressive behaviours: discontinuation study

1 reference

7 January 2021

A double-blind placebo-controlled discontinuation study of zuclopenthixol for the treatment of aggressive disruptive behaviours in adults with mental retardation - secondary parameter analyses.

1 reference

7 January 2021

Practitioner review: Psychopharmacology in children and adolescents with mental retardation

1 reference

7 January 2021

Open-label, prospective trial of olanzapine in adolescents with subaverage intelligence and disruptive behavioral disorders

1 reference

7 January 2021

Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism

1 reference

7 January 2021

Psychotropic medication in adults with mental retardation: prevalence, and prescription practices.

1 reference

7 January 2021

A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder.

1 reference

7 January 2021

Effects of Topiramate on Aggressive, Self-Injurious, and Disruptive/Destructive Behaviors in the Intellectually Disabled: An Open-Label Retrospective Study

1 reference

7 January 2021

Serotonergic antidepressant effects on aggressive, self-injurious and destructive/disruptive behaviours in intellectually disabled adults: a retrospective, open-label, naturalistic trial

1 reference

7 January 2021

Retrospective assessment of atomoxetine in children and adolescents with pervasive developmental disorders

1 reference

7 January 2021

Open-label study of olanzapine in children with pervasive developmental disorder

1 reference

7 January 2021

Treatment of aggressive children with clonidine: results of an open pilot study

1 reference

7 January 2021

Mood stabilizers and anticonvulsants

1 reference

7 January 2021

Functional analysis and treatment of self-injurious behavior in young children a summary of 30 cases

1 reference

7 January 2021

Effectiveness of zuclopenthixol compared with haloperidol in the treatment of behavioural disturbances in learning disabled patients.

1 reference

7 January 2021

Open-label quetiapine in the treatment of children and adolescents with autistic disorder.

1 reference

7 January 2021

Risperidone in children with autism and serious behavioral problems

1 reference

7 January 2021

Case series: use of ziprasidone for maladaptive symptoms in youths with autism

1 reference

7 January 2021

Effects of methylphenidate treatment in children with mental retardation and ADHD: individual variation in medication response.

1 reference

7 January 2021

Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity

1 reference

7 January 2021

Psychopharmacotherapy in children and adults with intellectual disability

1 reference

7 January 2021

Severe non-anion gap metabolic acidosis induced by topiramate: a case report

1 reference

7 January 2021

The use of risperidone among individuals with mental retardation: clinically supported or not?

1 reference

7 January 2021

A double-blind comparison of zuclopenthixol tablets with placebo in the treatment of mentally handicapped in-patients with associated behavioural disorders

1 reference

7 January 2021

Psychopharmacoepidemiology of mental retardation: 1966 to 1995.

1 reference

7 January 2021

Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs.

1 reference

7 January 2021

Zuclopenthixol treatment of behavioral disturbances in mentally retarded children and adolescents: an open-label study.

1 reference

7 January 2021

A naturalistic retrospective analysis of psychostimulants in pervasive developmental disorders.

1 reference

7 January 2021

Aripiprazole for maladaptive behavior in pervasive developmental disorders

1 reference

7 January 2021

Psychotropic drug use in intellectually disabled group-home residents with behavioural problems.

1 reference

7 January 2021

Prevalence of psychiatric diagnoses in children with mental retardation: data from a population-based study

1 reference

7 January 2021

Self-injurious behavior and the efficacy of naltrexone treatment: a quantitative synthesis

1 reference

7 January 2021

Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomised controlled trial

1 reference

7 January 2021

Systematic recording of behaviors and skills of retarded and psychotic children

1 reference

7 January 2021

Effects of risperidone on destructive behavior of persons with developmental disabilities: III. Functional analysis

1 reference

7 January 2021

Identifiers

DOI

10.1002/DDRR.119

1 reference

23 August 2017

1 reference